Table 1.
Patient and disease characteristics at baseline.
| Patients (n = 41) | |
|---|---|
| Sex, n (%) | |
| Female | 22 (54%) |
| Male | 19 (46%) |
| Age, median (range), years | 62 (43–81) |
| Tumour types, n (%) | |
| Colorectal | 27 (66%) |
| Non-small-cell lung cancer | 11 (27%) |
| Pancreatic | 3 (7%) |
| ECOG PS, n (%) | |
| 0 | 16 (39%) |
| 1 | 25 (61%) |
| Number of prior lines of therapy, n (%) | |
| 0 | 1 (2%) |
| 1 | 7 (17%) |
| 2 | 13 (32%) |
| ≥3 | 20 (49%) |
| KRAS mutation, n (%) | |
| Exon 2 | 36 (88%) |
| Exon 3 | 3 (7%) |
| Exon 4 | 2 (5%) |
ECOG PS Eastern Cooperative Oncology Group performance status, KRAS Kirsten rat sarcoma viral oncogene homologue.